NeuroInsights, the neurotech market authority, announced the release of its’ seventh annual investment guide and market analysis of the global neurological disease and psychiatric illness markets. Unveiled during the annual Neurotech Investing and Partnering Conference in San Francisco, this 550-page report enables investors, companies and governments to assess opportunities, calculate risks and understand the dynamics of this continually changing market.
“Overall, the industry continues to grow despite pressure on pharmaceutical prescriptions for chronic diseases due to the economic downturn and generic competition,” said Casey Lynch, Managing Director of NeuroInsights, “Neurodevice revenues, including innovative neurovascular and neuromodulation devices, continue to grow at double digit rates. Neurodiagnostic revenues swung into positive territory again and large companies began to snatch up some of the smaller companies on the cutting edge of brain monitoring and diagnostic testing.”
Specific findings from the Neurotechnology Industry 2011 Report show that in 2010:
• Global neurotech industry revenues grew 3.2% to $149.8 billion
• Neuropharmaceuticals recorded revenues of $126.6 billion with 2.8% annual growth
• Neurodevices recorded revenues of $7.98 billion with 13% annual growth
• Neurodiagnostics recorded revenues of $15.3 billion and 2% annual growth
• Brain-related illness is the largest unmet medical market, two billion people worldwide
• Venture capital investment in neurotechnology was down 40% to $975 million
• More than 250 venture investors participated in neurotech financings in 2010
• The NASDAQ NeuroInsights Neurotech Index (^NERV) was up 32% in 2010
Detailed data from the report are being presented during the 6th annual Neurotech Industry Investing and Partnering Conference, co-hosted by the Neurotechnology Industry Organization and NeuroInsights. This conference, being held at the St. Regis Hotel today and tomorrow, is the premier global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry.
“The record number of attendees at this meeting is a testament to massive unmet need and progress being made across neurotechnology,” said Zack Lynch, founder of the Neurotechnology Industry Organization. “With an annual economic burden of $1.4 trillion in the US alone, it is critical that the companies developing new treatments and diagnostics for the brain and nervous system have an opportunity to meet with investors and partners across commercial neuroscience.”
The Neurotechnology Industry 2011 Report: Drugs, Biologics, Stem Cells, Devices and Diagnostics for the Brain and Nervous System tracks developments and helps guide strategic business development and investment decisions in neurotech. This year’s report provides an in-depth look at more than 18 brain and nervous system disorders and treatments in development at over 550 public and private companies, including: Alzheimer’s disease, addiction, ADHD, anxiety, depression, epilepsy, migraine, mild cognitive impairment, multiple sclerosis, obesity, pain, Parkinson’s disease, schizophrenia, retinal disorders, sleep disorders, stroke and traumatic brain injury. Corporate financing, market activity, growth drivers and global industry conditions that make up the obstacles and opportunities facing the industry are fully assessed with detailed insights.
Date: May 9, 2011
Source: NeuroInsights
